Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

Stopped Study has voluntarily discontinued due to a change in the company-level development strategy and is not because of any safety concern or the request from any health authority worldwide.

Conditions

• Hepatocellular Carcinoma

Interventions

• DRUG: Sitravatinib
• DRUG: Tislelizumab
• DRUG: sitravatinib-matching placebo
• DRUG: tislelizumab-matching placebo

Sponsor

BeiGene